Aspartate-β-hydroxylase induces an epitope-specific T cell response in tumors

摘要

PROBLEM TO BE SOLVED: To provide a peptide-based immunotherapy for ASPH-expressing tumor. A composition comprising a therapeutically effective amount of a purified aspartate-β-hydroxylase (ASPH) peptide, the peptide comprising at least 7 amino acids in length and less than the full-length ASPH protein. And a composition comprising HLA class I or class II restricted epitope sequences. [Selection diagram] Fig. 6